Depomed, Inc., of Menlo Park, Calif., has received approval for 1,000-mg strength tablets of Glumetza (metformin hydrochloride extended-release tablets), which is indicated alone or in combination with a sulfonylurea or insulin as an adjunctive therapy to improve glycemic control in adult type 2 diabetes patients.
“This approval is good news for patients with type 2 diabetes who are on metformin therapy and prefer to take fewer tablets per day,” stated Carl A. Pelzel, president and chief executive officer of Depomed. “We now have two ways for patients to achieve 24-hour glycemic control: the original Glumetza 500-mg tablets, which start out as small, easy-to-swallow tablets that expand once in the stomach, and the new 1,000-mg tablets, which require fewer tablets to hit the target dose.”
Continue Reading
Depomed and its commercial supplier, Biovail, expect to market the tablets commercially in the near future.
